pifithrin has been researched along with Cancer of Nasopharynx in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, C | 1 |
| Guan, Y | 1 |
| Zeng, L | 1 |
| Liu, G | 1 |
| Zhu, Y | 1 |
| Xu, H | 1 |
| Lu, Y | 1 |
| Liu, J | 1 |
| Guo, J | 1 |
| Feng, X | 1 |
| Zhao, X | 1 |
| Jiang, W | 1 |
| Li, G | 2 |
| Dai, Y | 1 |
| Jin, F | 1 |
| Li, W | 1 |
| Zhou, W | 1 |
1 other study available for pifithrin and Cancer of Nasopharynx
| Article | Year |
|---|---|
High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell | 2018 |